$1 billion to end MS: is a cure finally within reach?
The National MS Society has launched a $1 billion campaign. I examine the three pathways to a cure, genuine breakthroughs and what nobody can promise yet.
“The end of multiple sclerosis is within reach.” I read that sentence twice. When you have lived with MS since 2010, a headline like that lands before you have time to analyse it. Hope comes first. Then the question: is this genuinely a historic moment — or the most expensive fundraising campaign in MS history?
On 1 October, the US National Multiple Sclerosis Society launched the Campaign to End MS, a five-year effort to raise $1 billion. The money is intended to accelerate research, widen access to care and support people affected by MS [1](#ref-1). More than $12 million was raised on the opening night [2](#ref-2).
> This is big news. But “within reach” does not mean a cure arrives next year. It means science has clearer targets than ever — and the campaign wants the money to hit them faster.
Why they said for the first time that ending MS is possible
The Society has existed for eighty years and has never officially said before that MS can be ended. Its president, Tim Coetzee, said the question is no longer if, but how quickly [1](#ref-1). It is a powerful line, but it comes from an organisation launching a billion-dollar campaign. It is both a scientific ambition and a call to donors.
Still, it is not invented from nothing. The Society currently supports more than 200 research projects and says it has over $100 million invested in active MS research. Alongside the campaign it announced another $8.9 million for 15 projects aligned with its Pathways to Cures roadmap [1](#ref-1). That roadmap is not an advertising slogan; it was published in a peer-reviewed journal and endorsed across the international MS community [3](#ref-3), [4](#ref-4).
Three roads to the goal: stop, restore, prevent
A “cure” is not one pill or one spectacular day. The research roadmap splits the work into three paths that eventually have to meet.
STOP the disease. The goal is no new relapses, lesions or silent disability progression. Today’s DMTs already suppress relapses very effectively for many people, yet progression can continue without them. Researchers are therefore pursuing treatments that work inside the brain and spinal cord, against chronic active lesions and the mechanisms that damage nerves.
RESTORE lost function. This is the hardest part: repairing myelin, protecting axons and allowing the nervous system to regain what the disease has taken. I have covered research attempting exactly that in the articles on [kamuvudine K-9](/en/blog/kamuvudine-k9-hiv-drug-multiple-sclerosis-inflammasome) and [the ATDR molecule and remyelination](/en/blog/a-newly-discovered-molecule-atdr-helps-repair-myelin-restore-nerve-ms).
END MS before it begins. That means identifying people at high risk, removing triggers and eventually preventing the first case. A few years ago it would have sounded like science fiction. Today one discovery makes it sound less so: Epstein–Barr virus.
EBV is the strongest case that MS may one day be preventable
A study of more than ten million US military personnel found that the risk of MS rose roughly 32-fold after Epstein–Barr virus infection, while the same pattern was not seen with other viruses [6](#ref-6). EBV is now considered the leading causal candidate for MS, although the virus alone is not sufficient — almost every adult carries it and only a small minority develop MS [7](#ref-7).
If EBV is a necessary link in the chain, a vaccine or antiviral could one day break that chain before disease begins. An mRNA-1189 vaccine candidate is already in an early human study [8](#ref-8). But no EBV vaccine has been shown to prevent MS. Proving that will take large, long trials because MS usually appears years after infection.
That is what “within reach” really means here: for the first time there is a plausible prevention target. It is not the same as validated prevention.
One billion dollars — enormous or not enough?
A billion dollars sounds almost unreal. Spread over five years, it is $200 million a year. The money is not intended for laboratories alone. The campaign promises diagnosis in hours rather than months or years, the right treatment at the right time, and support within reach of every person affected by MS [1](#ref-1). Part of the goal is making sure what we already know actually reaches people.
That matters in Serbia and the wider region too. A breakthrough in Boston changes nothing if someone in a smaller town waits months for an appointment, an MRI or a treatment decision. I wrote about those gaps in [MS centres across Europe and Serbia](/en/blog/ms-centres-across-europe-planned-centre-serbia-comparison). “Ending MS” must also mean ending delay, inequality and inaccessible treatment — otherwise it will exist only for people with the right postcode.
Where hope collides with reality
Drug development does not move in a straight line. In the large HERCULES trial, tolebrutinib reduced the risk of six-month confirmed disability progression in non-relapsing secondary progressive MS [9](#ref-9). It was the kind of result the community had waited years to see. Then, at the end of 2025, the FDA declined approval because it could not establish a favourable benefit–risk profile in light of serious liver injury [10](#ref-10).
The remyelination story is similar. Metformin plus clemastine in the CCMR Two trial produced a small repair signal on a visual-pathway conduction test, but did not improve disability or visual function at six months [11](#ref-11). The signal justifies more research. It does not mean lost sight or walking has been restored.
That is not a reason for cynicism. It is why hundreds of parallel projects are needed. Some will fail on safety, some will not work strongly enough, and one may open an entirely new road.
What the campaign promises an ordinary person
Its three public promises are simple: diagnosis in hours rather than months or years; the right treatment at the right time for everyone; and support that leaves nobody to face MS alone [1](#ref-1). None of those requires waiting for the final cure.
Early diagnosis and early effective treatment already reduce damage. Better biomarkers, accessible MRI and clearer criteria can shorten the diagnostic limbo. Registries, telemedicine, rehabilitation and family support can change a life before the next scientific breakthrough arrives.
For me, that is the most important part of the campaign. I do not want “ending MS” to be a line that looks good at a New York gala. I want it to mean that the person diagnosed today will not have to wait, beg and search the internet alone for explanations.
Will a giant campaign really end the disease?
Nobody can honestly promise that today. About 2.9 million people worldwide live with MS [13](#ref-13), and there is still no therapy that simultaneously stops every form of disease activity, repairs old damage and prevents new cases. The campaign has a five-year timetable; biology is under no obligation to meet a fundraising deadline.
But three things are now on the table at once: powerful drugs that control inflammation, concrete attempts to repair the nervous system, and a causal target that opens the possibility of prevention. Add a billion dollars, international collaboration and the patient voice, and “within reach” is no longer empty. It is simply not the same as “we already have a cure.”
What you can do
If you live with MS, the priority remains what is available today: regular reviews, timely DMT treatment, rehabilitation, stopping smoking, movement adapted to your ability and discussing any symptom change with your neurologist. Do not stop treatment while waiting for a research breakthrough.
If you want to support research, follow clinical-trial registries, ask your centre whether you may qualify for a study, support reputable MS organisations and share reliable information. Donating is one route; participating, advocating and challenging misinformation are others.
I will follow this campaign with hope, but without surrendering judgement. After sixteen years with MS, I know how badly we need a big sentence. I also know how much it hurts when one becomes a false promise. So my answer is this: the end of MS may be closer than ever — but we will reach it through evidence, not a headline.
This article is educational and does not replace examination or advice from a neurologist. The Campaign to End MS is a research and humanitarian initiative; there is currently no treatment that cures multiple sclerosis.